ALK and non-small cell lung carcinoma: Furthermore, the present study is to our knowledge the first real-world analysis to include a reasonably sized ALK+ NSCLC cohort evaluable for OS, and the first to systematically examine the effect of molecular tumor characteristics on intracranial disease control.